The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion | Scientific Reports
Clinical trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis | Radiation Oncology | Full Text
Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment | Radiation Oncology | Full Text
Non-Small Cell Lung Cancer
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
![PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7cbf64e0a2a5bc6572dc331e433efae660922309/4-Figure1-1.png "PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar")
PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar
Overall survival curves of patients with lung cancer. The 5-year... | Download Scientific Diagram
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
Stereotactic ablative radiotherapy shows long-term benefit in operable early NSCLC
Postoperative Survival of Lung Cancer Patients: Are There Predictors beyond TNM? | Anticancer Research
Kaplan-Meier survival analyses of overall survival (A) and lung... | Download Scientific Diagram
EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer | NEJM
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
Real-world treatment and survival in early-stage NSCLC - Medical Conferences
Purpose
Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014 | PharmacoEconomics - Open
Education & Resources for Oncology Nurses – IMFINZI® (durvalumab)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
Overall survival by clinical stage according to the seventh edition (A)... | Download Scientific Diagram
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug - ScienceDirect
Cancers | Free Full-Text | Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer
Prognostic factors in resected pathological N1-stage II nonsmall cell lung cancer | European Respiratory Society
